Analystreport

KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.

Kala Pharmaceuticals, Inc.  (KALA) 
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kalarx.com